GENEREX BIOTECHNOLOGY CORP
CompletedSpin-offSpun off from Generex Pharmaceuticals
The two companies
Open either company's hub for its full SEC financials, ratios, ownership, filings, and every other event it's been part of.
- Sector
- Other
- Industry
- —
- Exchange
- —
- State of incorporation
- —
- Record date
- —
- Distribution date
- —
- Ratio
- —
- Parent sector
- —
- Form
- 10-12G
- Filed
- December 14, 1998
Financials — parent vs spin-off
SEC XBRL · latest yearNo XBRL financials available.
- Revenue
- —
- Operating income
- −$18M
- Net income
- −$34M
- Total assets
- $45M
- Equity
- −$12M
Latest reported figures from each company's own SEC filings — the parent after the separation and the spin-off as a standalone. Full multi-year history on each company hub.
Spin-off signals
score 1/5 favorable · factors, not advice- Leverage (liabilities/assets)117%
A heavy debt load loaded onto the spin-off is a known risk; a clean balance sheet is favorable.
- Return on capital employed-447.1%
EBIT ÷ capital employed — the quality metric the spin-off scorecard research weighs most.
- Tax-basis reportNone found
A Form 8937 (basis allocation) accompanies tax-free §355 spin-offs — favorable for taxable holders.
- Insider buying (post-spin)2 open-market buys
Officers/directors buying their own newly independent shares (Form 4) has historically preceded outperformance.
- Time since spin-off27.5 years
Studies find the spin-off return premium concentrates in roughly the first one to three years.
Factors the spin-off research literature (Greenblatt; Cusatis-Miles-Woolridge; Desai-Jain) associates with outcomes — computed from this company's own SEC filings, shown as factors, not a recommendation. The premium is debated and not guaranteed. How we compute these ↗
Filings & documents
Every entry traces to SEC EDGAR. The Information Statement is the primary source; the links below open the full filing and each company's complete filing history.